Portola leads with $60M round

CompanyAmount/RoundLead InvestorsDescription
Portola Pharmaceuticals
South San Francisco
$60M
FThird
D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK

Most of the funding will be used to advance Portola's lead drug betrixaban.

Light Sciences Oncology
Bellevue, WA
$40.1
Third
Unnamed

The funding will be used to advance its work on light infusion therapies.

Dicerna Pharmaceuticals
Cambridge, MA
$8.4M
First
Abingworth, Oxford Bioscience Partners and Skyline Ventures

Dicerna Pharmaceuticals is an RNA interference company.

Portola leads with $60M round

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.